The team is working on target-based drug delivery for cancer treatment. The Company has designed a platform technology with a novel concept of triple conjugate i.e., Drug-Protein-Polymer-Conjugate (DPPC) for the purpose. Based on specificity of the target organ, various components of DPPC can be rationally selected. Benefits offered by the technology:

  • Highly target specific and selective drug delivery system to a defined population of cells/organ(s) for chronic disease therapy like cancer.
  • Minimized uptake of an active drug, by normal cells and enhances the influx and retention of the drug in target cells/ tissues/ organs.
  • Provides a pharmaceutical formulation which is administered as a single unit dose through IV route of administration having better patient compliance.
  • Lower dose and reduced frequency of the administration of a drug in comparison to individual use of the drug or known drug-polymer or known protein polymer conjugates.
  • Improved availability of the drug molecule at target site and reduction in side effects due to targeted delivery and sustained release.

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to VRL India, its subsidiaries or affiliates. No use of any VRL India trademark, trade name, or trade dress in this site may be made without the prior written authorization of VRL India, except to identify the product or services of the company.

Back to Top